Sjögren’s Syndrome Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMPH26 | Last Updated On: Jun 13 2022 | Available Formats

> Global Sjögren’s Syndrome Market Expected to reach a high CAGR of 3.3% during the forecast period 2022-2029: DataM Intelligence

Global Sjögren’s Syndrome Market is segmented By Drug Class (Cholinergic Agonists, Off-Label Drugs), By Type (Primary Sjogren’s Syndrome, Secondary Sjogren’s Syndrome), By Distribution Channel (Hospitals, Retail Pharmacy, Online Pharmacy), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029


Market Overview

GlobalSjögren’s Syndrome Market is expected to grow at a CAGR of 3.3% during the forecasting period (2022-2029)

  • Sjögren’s syndrome (SS) is a chronic, autoimmune, systemic, inflammatory disorder of unknown cause.
  • It is characterized by dryness of the mouth, eyes, and other mucous membranes due to lymphocytic infiltration of exocrine glands and secondary gland dysfunction.
  • There is currently no cure for Sjögren’s syndrome, but there are treatments that can help relieve the symptoms.

Market Growth:

  • Global Sjögren’s syndrome market will reach USD 2 billion by 2024, driven primarily by the launch of Bristol-Myers Squibb’s Orencia from 2021.
  • Other factors driving the market include the growing patient population of diseases that can cause SS such as lupus and rheumatoid arthritis.
  • Increasing awareness and hence the demand for advanced treatment.
  • However, the lack of a cure for Sjögren’s syndrome will impact market growth.
  • Many of the currently available treatments for SS either only relieve the symptoms or are considered ineffective in many patients.

Market Segmentation:

  • Global Sjögren’s syndrome market report segments the market by type, by drug class, by distribution channel, and by region.
  • Based on the type, the market is segmented into primary Sjogren’s syndrome and secondary.
  • Secondary Sjogren’s syndrome segment dominates the market.
  • Geographically, the market is segmented into five major regions, namely North America, South America, Europe, Asia Pacific, and RoW.
  • North America is the largest market for Sjögren’s syndrome owing to the rising prevalence of autoimmune diseases and advanced autoimmune diagnostic testing and screening.

Market Scope of the Report:

  • The report also profiles companies in the Sjögren’s syndrome market – Novartis AG, Allergan Inc., Otsuka Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., Nicox S.A., Argentis Pharmaceuticals, LLC., Auven Therapeutics, Bridge Pharma Inc. and Cellzome GmbH.

By Drug Class

  • Cholinergic Agonists
  • Off-Label Drugs

By Type

  • Primary Sjogren’s Syndrome
  • Secondary Sjogren’s Syndrome

By Distribution Channel

  • Hospitals
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • Asia Pacific (China, Japan, India, Australia, Rest of Asia Pacific)

  • Europe (Germany, France, The UK, Italy, Spain, Rest of Europe)

  • North America (The USA, Canada, Mexico)

  • South America (Brazil, Argentina, Rest of South America)

  • Rest of the World

Trending Topics

Polycystic Ovary Syndrome Market

Marfan Syndrome Treatment Market

Remote Patient Monitoring Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!